Espectro clínico de neuromielite óptica

Study of Ultomiris® (Ravulizumab) Safety in Pregnancy

NCT06312644

A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)

NCT05199688

Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.

NCT07526493

Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study

NCT07410039

Modified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder

NCT07420296

NCT06312644 · Study of Ultomiris® (Ravulizumab) Safety in PregnancyRecrutando

🟢 Recrutando agora

19 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

NCT05199688 · A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tole…Recrutando

PHASE3

NCT07526493 · Safety and Pharmacodynamics of QH103 Cell Injection in the T…Recrutando

PHASE1

NCT07410039 · Therapy in the Acute Phase of NMOSD: A Multicenter Prospecti…Recrutando

PHASE4

NCT07420296 · Modified Zipper Therapy for AQP4-IgG Positive Neuromyelitis …Recrutando

PHASE4

NCT05966467 · Registry of Patients With AQP4+ NMOSD Treated With Alexion C…Recrutando

NCT05504694 · Ofatumumab in AQP4-IgG Seropositive NMOSDRecrutando

PHASE1, PHASE2

NCT05909761 · Observational Safety Study in Women With Neuromyelitis Optic…Recrutando

NCT06620809 · The Safety and Efficacy of NouvSoma001 in Neuromyelitis Opti…Recrutando

PHASE1

NCT03900221 · French Registry for Monitoring Pregnancies for Multiple Scle…Recrutando

NCT06939166 · Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） The…Recrutando

EARLY_PHASE1

NCT05549258 · Study of Inebilizumab in Pediatric Subjects With Neuromyelit…Recrutando

PHASE2

NCT05346354 · Efficacy and Safety Study of Ravulizumab IV in Pediatric Par…Recrutando

PHASE2, PHASE3

NCT07202494 · Integrating Metabolism, Connectivity, and Mesoscale Imaging …Recrutando

NCT07184840 · Eculizumab For the Acute Attack of Neuromyelitis Optica Spec…Recrutando

PHASE2

NCT06398158 · Study of the Clinical and Radiological Impact of Ravulizumab…Recrutando

NCT04886492 · CorEvitas SPHERES (Synergy of Prospective Health & Experimen…Por convite

NCT06643858 · Normal Chinese Lifespan Brain Charts Initiative (NCLBCI)Por convite

NCT06374264 · Acceptability and Safety of MR-C-014 in Persons With Neuromy…Por convite

NA

Outros ensaios clínicos

173 ensaios clínicos encontrados, 30 ativos.

Distribuição por fase

NCT00716066 · Autologous Stem Cell Transplant for Neurologic Autoimmune Di…Ativo

PHASE2

Ver todos no ClinicalTrials.gov

🧪 Está conduzindo uma pesquisa?

Divulgue para pacientes e familiares que acompanham esta doença.

Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações

3.055 papers (10 anos)

Mostrando amostra de 200 publicações de um total de 3.055

#1

Paraneoplastic neuromyelitis optica spectrum disorder with dual AQP4-IgG and CRMP5 antibodies following thymectomy: a case report.

Frontiers in neuroscience2026

We present a rare case of paraneoplastic neuromyelitis optica spectrum disorder (NMOSD) in a 50-year-old woman with a history of B3 thymoma, marked by dual positivity for AQP4-IgG and CV2/CRMP5 antibodies. The patient developed sequential bilateral optic neuritis, with orbital MRI revealing enhancement of the left optic nerve. Serological analysis showed a high AQP4-IgG titer (1:320) and positive CV2/CRMP5 antibodies, while other paraneoplastic markers were absent. Treatment with glucocorticoids and mycophenolate mofetil led to substantial visual recovery. This case underscores the association between thymoma and paraneoplastic NMOSD and suggests a potential interaction between AQP4- and CRMP5-related autoimmune responses. Although CV2/CRMP5 antibodies are typically linked to lung cancer and thymoma, their coexistence with AQP4-IgG in NMOSD points to a distinct paraneoplastic mechanism. These findings support the need for thorough tumor screening in NMOSD patients with atypical features, particularly those with CV2/CRMP5 seropositivity.

#2

Human umbilical cord mesenchymal stromal cells therapy for neuromyelitis optica spectrum disorder: a phase 1/2a trial.

Cell death and differentiation2026 Mar 17

Current treatments for neuromyelitis optica spectrum disorder (NMOSD) highlight recurrence management, while little attention is paid to the relief of residual neurological dysfunction. Here we aimed to evaluate the safety and efficacy of human umbilical cord-derived mesenchymal stromal cells (hUC-MSCs) in reducing relapses and mitigating neurological impairments. This trial, hUC-MSC-NMOSD (ChiCTR-INR-16008037), a single-arm, dose-escalation, open-label study, included 31 NMOSD patients of three dose groups received four infusions every three months, with 15-month follow-up. Primary outcome was time to first recurrence; secondary outcomes focused on clinical scores, MRI lesions and exploratory findings. HUC-MSC infusion was well tolerated in all groups of patients. Adverse events were mostly mild, with urinary tract infections being the most common. Severe adverse events were rare and unrelated to the treatment. The median relapse-free interval increased significantly post-treatment from 305 (95%CI 226-382·5) to 760 (589-1016·5) (p < 0·001), especially in the medium- and high-dose groups. During the two years before and after therapy, the mean Annualized Relapse Rate (ARR) dropped considerably from 1 (0·75-1) to 0 (0-0·5) (p < 0·001). Clinical scores improved in the low and medium-dose groups. The total volume of high-signal white matter lesions in brain significantly decreased after therapy from 4144·5 (2857·2-5508·6) to 2914·4 (2453-3684·11) (p = 0·016). Exploratory single-cell RNA sequencing and metabolomics detection revealed a potential participation of thioredoxin and oxidative phosphorylation (OXPHOS)-mediated boosting of Treg differentiation and suppressive capacity. This trial indicates that intravenous hUC-MSC administration is safe and shows potential efficacy in treating NMOSD. Medium dose might be the best possible compromise between safety and effectiveness.

#3

Frequency of AQP4 and MOG Antibodies in Patients With Optic Neuritis Fulfilling Minimal New Multiple Sclerosis MRI Criteria.

Neurology2026 Apr 14

Recent revisions to multiple sclerosis (MS) diagnostic criteria include the optic nerve as a site of dissemination in space, enabling this diagnosis in patients with acute optic neuritis (ON) and a single additional MS-typical location on MRI if dissemination in time (DIT) is demonstrated. We aimed to assess the frequency of non-MS diagnoses in this context. We retrospectively analyzed consecutive patients with inaugural acute ON and at least 1 MS-typical lesion in a single brain location on baseline MRI across 3 French centers. All patients met DIT criteria and underwent aquaporin-4 (AQP4) and myelin oligodendrocyte glycoprotein (MOG) antibody testing. Final diagnoses were based on clinical, radiologic, and follow-up data. Among 96 patients (mean age 35.8 years; 70.8% female), 73 (76.0%) were diagnosed with MS and 23 (24.0%) with MOG antibody-associated disease (n = 18) or neuromyelitis optica spectrum disorder. Longitudinally extensive lesions, bilateral involvement, chiasmal enhancement, or optic perineuritis were observed in 100% of non-MS patients and 24.6% of patients with MS (difference 75.4%, 95% CI: 64.3-86.6; p < 0.001). All patients without these patterns were ultimately diagnosed with MS. AQP4 and MOG antibody testing, along with careful orbital MRI interpretation, is recommended in patients with ON meeting minimal new MS criteria.

#4

Real-world safety of satralizumab in neuromyelitis optica spectrum disorder: a FAERS-based risk stratification study.

Journal of neurology2026 Mar 17

Satralizumab, an interleukin-6 receptor monoclonal antibody, is an established therapy for neuromyelitis optica spectrum disorder (NMOSD). While randomized trials have demonstrated their efficacy and short-term safety, real-world data characterizing report-level associations and severe adverse outcomes remain limited. We performed a retrospective pharmacovigilance study using the U.S. FDA Adverse Event Reporting System (FAERS) from Q1 2004 to Q3 2025. Disproportionality analyses (reporting odds ratios [RORs], information components [ICs]), subgroup analyses, co-medication analysis, time-to-onset evaluation, and multivariable logistic regression for most severe outcomes (death/life-threatening events) were conducted. Among 1174 satralizumab-related reports, infections were the most prominent signals, with key signals including atypical mycobacterial infection (ROR 109.24, 95% CI 51.92-229.82; IC 6.76, IC025 1.88), pneumonia pneumococcal (ROR 41.51, 95% CI 13.36-128.94; IC 5.37, IC025 0.45), and pyelonephritis (ROR 40.80, 95% CI 25.32-65.75; IC 5.34, IC025 2.98). Forty unlabeled events (e.g., lymphocyte count decrease [ROR 18.52, 95% CI 11.33-30.27]) were identified. Concomitant corticosteroid use was associated with increased reporting of infectious and hepatic adverse events. Among 827 reports with complete demographic data, 72 were classified as most severe. Factors associated with severe outcome reports included age ≥ 65 years (adjusted odds ratio [OR] 3.85, 95% CI 2.22-6.69), male sex (adjusted OR 2.23, 95% CI 1.20-4.15), and septic shock (adjusted OR 7.88, 95% CI 2.48-25.09). Median time to onset was 97 days (interquartile range 15-291 days), with early and late peaks. This real-world study highlights clinically relevant safety signals of satralizumab in NMOSD, identifies vulnerable patient subgroups, and supports risk-adapted monitoring strategies in neurological practice.

#5

Early anti-C5 therapy in NMOSD: rationale and clinical evidence.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2026 Mar 14

Complement-mediated astrocyte injury is central to aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder (AQP4-IgG+ NMOSD). Although C5 inhibitors are approved for relapse prevention, their role as rescue therapy during severe acute attacks remains unclear.We describe a 39-year-old woman with AQP4-IgG+ NMOSD presenting with longitudinally extensive myelitis, optic neuropathy, and a basal ganglia lesion. Despite two courses of intravenous methylprednisolone, five plasma exchanges, and intravenous immunoglobulin, disability progressed to an Expanded Disability Status Scale (EDSS) score of 9.0. Ravulizumab was initiated on day 34 after meningococcal vaccination and prophylactic antibiotics. Clinical course, cerebrospinal fluid (CSF) parameters, and total hemolytic complement activity (CH50) were followed for 1 year. After a 2400-mg loading dose of ravulizumab, CH50 became undetectable, indicating effective terminal complement inhibition, whereas C3/C4 remained within reference ranges. Neurological deterioration stopped promptly, followed by marked recovery in motor and visual function. EDSS improved from 9.0 to 6.0 at transfer and to approximately 1.5-2.0 at 1 year. CSF pleocytosis and protein levels normalized in parallel with CH50 suppression. The patient regained ambulation with an orthosis, returned to work on day 220, and remained relapse-free without treatment-related adverse events during 8-weekly maintenance therapy. This case supports the biological plausibility and practical feasibility of early ravulizumab rescue therapy in severe refractory AQP4-IgG+ NMOSD. Prospective studies are needed to define optimal timing, patient selection, and the incremental benefit beyond prior acute immunotherapies.

Publicações recentes

Exploring medication adherence and illness perception in patients with neuroimmune diseases: a cross-sectional study.

Front Immunol2026

Cardiovascular risk profiles among patients with multiple sclerosis and neuromyelitis optica spectrum disorder in Taiwan.

J Formos Med Assoc2026 Apr 15

Efficacy and safety of conventional immunosuppressant therapies in elderly patients with Neuromyelitis optica spectrum disorder: A target trial emulation study.

J Neurol Sci2026 Apr 7

Comparative Effectiveness of Disease-Modifying Treatments in Double Seronegative Neuromyelitis Optica Spectrum Disorder.

Neurol Neuroimmunol Neuroinflamm2026 May

Biologic therapy and brain atrophy in neuromyelitis optica: a Japanese-German longitudinal MRI study.

J Neurol Neurosurg Psychiatry2026 Apr 15

Ver todas no PubMed

📚 EuropePMC1.718 artigos no totalmostrando 200

Frontiers in neuroscience

Paraneoplastic neuromyelitis optica spectrum disorder with dual AQP4-IgG and CRMP5 antibodies following thymectomy: a case report.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

Two cases with overlapping features of multiple sclerosis and neuromyelitis optica spectrum disorder.

Nationwide prevalence and incidence of MOG antibody-associated disease (MOGAD) in Denmark.

Divergent comorbidity profiles in neuromyelitis optica spectrum disorder and multiple sclerosis: A large single-centre cohort from Turkey.

Intractable Nausea as the Initial Presentation of Neuromyelitis Optica.

Case Report: Rare co-occurrence of NMOSD and capillary leak syndrome treated with satralizumab.

Pregnancy before and after NMOSD diagnosis: a retrospective study highlighting the challenges in a referral center in Brazil.

Obstetric medicine

Balint syndrome as the initial presentation of neuromyelitis optica spectrum disorder.

Revue neurologique

Case Report: Recurrent sinus arrest induced by repeated vomiting.

Frontiers in physiology

Cell death and differentiation

Human umbilical cord mesenchymal stromal cells therapy for neuromyelitis optica spectrum disorder: a phase 1/2a trial.

Frequency of AQP4 and MOG Antibodies in Patients With Optic Neuritis Fulfilling Minimal New Multiple Sclerosis MRI Criteria.

Real-world safety of satralizumab in neuromyelitis optica spectrum disorder: a FAERS-based risk stratification study.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

Early anti-C5 therapy in NMOSD: rationale and clinical evidence.

EEG biomarkers of microstructural damage in normal-appearing white matter among patients with neuromyelitis optica spectrum disorder: A DTI-EEG combined study.

CAR T cell therapy in autoantibody-mediated neurological disorders: a promising strategy.

Impact of Anti-CD20 Therapies on Cytokine, Chemokine and Adhesion Molecule Dynamics in Multiple Sclerosis: A Narrative Review.

Neurology and therapy

Prevalence and Relative Proportions of Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder, and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease in the Republic of Korea.

Risk Stratification and Ventilator Liberation in Neuromyelitis Optica Spectrum Disorder-Related Central Respiratory Failure.

Neurocritical care

Neuromyelitis Optica Spectrum Disorder in a Pediatric Patient Following Haploidentical Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia.

Blood cell therapy

Science translational medicine

Aberrant bone marrow granulopoiesis generates neutrophils that promote B cell activity in neuromyelitis optica spectrum disorder.

Low Incidence of Relapses After Vaccination in Anti-Aquaporin-4 Antibody-Positive NMOSD.

Clinical neurology and neurosurgery

Protein A immunoadsorption for refractory neuromyelitis optica spectrum disorder: A prospective single-center study.

Relapse risk factors in double seronegative neuromyelitis optica spectrum disorder: Insights from a multicenter study.

Epstein-Barr Virus Antibodies to Differentiate Multiple Sclerosis From Other Neuroinflammatory Diseases.

JAMA neurology

Journal of translational autoimmunity

Intrathecal immunoglobulin production in the diagnosis, prognosis, and monitoring of autoimmune diseases of the central nervous system.

Optical Coherence Tomography Changes in Central Nervous System Inflammatory Demyelinating Diseases: A Longitudinal Retrospective Study.

The British and Irish orthoptic journal

Isolated Sixth Cranial Nerve Palsy as the First Presenting Sign of MOG Antibody-Associated Disease in a Three-Year-Old Child.

Microstructure-informed deep learning improves thalamic atrophy segmentation and clinical associations in multiple sclerosis and related neuroimmunological diseases.

NeuroImage. Clinical

Clinical, radiological, and CSF features distinguishing spinal dural arteriovenous fistula from idiopathic transverse myelitis and seropositive NMOSD-/MOGAD-associated myelopathy: a retrospective observational study.

Scientific reports

Impact of Age at Onset on Relapse and Disability in AQP4-IgG Neuromyelitis Optica Spectrum Disorder.

Annals of Indian Academy of Neurology

Trident Sign in Neuromyelitis Optica Spectrum Disorder.

Multiple sclerosis (Houndmills, Basingstoke, England)

Safety and efficacy of ravulizumab in patients with NMOSD previously treated with rituximab: A post hoc analysis of the CHAMPION-NMOSD trial.

Cell death and differentiation

ACSL4-mediated astrocyte ferroptosis augments neuroinflammation and exacerbates NMOSD pathology.

Prognosis biomarkers in MOGAD: What can we learn from observational studies?

Revue neurologique

Journal of clinical neurology (Seoul, Korea)

Consistent Detection of Aquaporin-4 Antibodies: A Comparative Analysis Between Fixed and Live Cell-Based Assays.

The temporal sequence of myasthenia gravis and neuromyelitis optica spectrum disorder: a case report and systematic review of 74 patients.

Journal of the American College of Radiology : JACR

ACR Appropriateness Criteria® Demyelinating Diseases.

Journal of neurology, neurosurgery, and psychiatry

Safety of breastfeeding under monoclonal antibodies in the offspring of mothers with multiple sclerosis or neuromyelitis optica spectrum disorder.

Aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder (NMOSD) complicated with acute pancreatitis: A case report.

Medicine

European journal of cancer (Oxford, England : 1990)

Optic neuropathies induced by immune checkpoint inhibitors: A case series and systematic review of the literature.

European journal of neurology

Efficacy and Safety of Rituximab Versus Inebilizumab in Patients With Neuromyelitis Optica Spectrum Disorder: A Dual-Center, Real-World Cohort Study.

Journal of clinical medicine

Neuropathic Pain in Neuromyelitis Optica Spectrum Disorders: Prevalence and Management Strategies-A Systematic Review and Meta-Analysis.

Journal of psychosomatic research

Major depressive disorder in multiple sclerosis and AQP4-antibody positive neuromyelitis optica spectrum disorder: A cross-sectional study on clinical correlates in Iranian patients.

Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego

Rare demyelinating diseases of the central nervous system: A diagnostic and therapeutic challenge - based on the case of a young woman with MOGAD.

Intractable & rare diseases research

Comparative analysis of adverse event reporting signals between Satralizumab and Inebilizumab in neuromyelitis optica spectrum disorder: A pharmacovigilance study using the FDA Adverse Event Reporting System.

Multiple sclerosis (Houndmills, Basingstoke, England)

Long-term effectiveness and safety of satralizumab for neuromyelitis optica spectrum disorder in a real-world clinical setting in Japan: A 2.5-year final analysis of a multicenter medical chart review (The SAkuraBeyond Study).

Internal medicine (Tokyo, Japan)

Progress in the Treatment of Neuromyelitis Optica Spectrum Disorder: From Pathogenic Insights to Biologics.

A Modern Approach to Brown-Séquard Syndrome: A Case Report.

Current evidence and knowledge gaps in family planning and pregnancy in myasthenia gravis, NMOSD, and MOGAD.

The Lancet. Neurology

Clinical immunology (Orlando, Fla.)

Polymorphonuclear myeloid-derived suppressor cells inhibit natural killer cell function in neuromyelitis optica spectrum disorder via the CD155-TIGIT axis.

Monoclonal antibodies in neuromyelitis optica spectrum disorder: a systematic review and meta-analysis.

Neuromyelitis Optica Spectrum Disorder Initially Presenting With Meningitis-Like Symptoms: A Case Report.

Tremor and other hyperkinetic movements (New York, N.Y.)

Pseudoathetotic Pseudodystonia as a Manifestation of Isolated Medullary Demyelination in Neuromyelitis Optica Spectrum Disorder.

Clinica chimica acta; international journal of clinical chemistry

Exploration of the source of AQP4 antibody: Based on paired serum and cerebrospinal fluid samples from 98 patients.

International journal of molecular sciences

C-Reactive Protein and Neurological Autoimmune Diseases: Bridging the Diagnostic and Pathogenic Gap.

Journal of the neurological sciences

Persistent parvovirus B19 DNAemia in B-cell depletion: Implications for family planning in multiple sclerosis and related disorders.

Annals of medicine and surgery (2012)

Neuromyelitis optica - a cause for longitudinally extensive transverse myelitis: a rare case report from Nepal and literature review.

Annals of medicine and surgery (2012)

Neuromyelitis optica spectrum disorder in an 11-year-old: a case report in a pediatric patient from Nepal.

Internal medicine (Tokyo, Japan)

Diverticular Perforation with Normal C-reactive Protein in a Patient with Neuromyelitis Optica Spectrum Disorder Receiving Satralizumab.

Complement Inhibition for Acute Neuromyelitis Optica Spectrum Disorder Attacks: Insights From an International Case Series.

Proceedings of the National Academy of Sciences of the United States of America

Natalizumab exacerbates astrocytopathy in NMOSD via blockade of endothelial VCAM1-astrocytic integrin α4 interaction.

AQP4-IgG-Induced Astrocyte-Derived Small Extracellular Vesicles Carrying Mitochondrial DNA Regulate the TLR9/MyD88/NF-κB Pathway to Drive Microglial Activation and Neuromyelitis Optica.

Neurochemical research

Frontiers in ophthalmology

Long-term Indian optic neuritis study (THE LION STUDY): clinical, imaging features and visual behavior of optic neuritis in Indian population over two decades.

Quantitative ophthalmic posterior segment optical coherence tomography angiography and neurologic conditions: a review.

Annals of African medicine

An Unusual Case of Hypersomnolence.

Biomarkers for satralizumab treatment in neuromyelitis optica spectrum disorders: a prospective case series.

Associations between personality traits and cognitive function in multiple sclerosis and neuromyelitis optica spectrum disorder: A cross-sectional study.

The immunoproteasome as a neuroimmune hub in the central nervous system: from proteostasis stress to inflammatory pathology.

First demyelinating attack in children: A twelve year single center cohort.

Translational vision science & technology

Anti-IL-6 Receptor Antibody Suppresses Visual Dysfunction in AQP4 Peptide-Immunized Mice.

Neuro-ophthalmology (Aeolus Press)

Demographic and Epidemiological Profile of Optic Neuritis in Colombia: A Retrospective Study Using Data from the Comprehensive Information System for Social Protection.

Arquivos de neuro-psiquiatria

Double-seronegative neuromyelitis optica: it is not possible to interrupt treatment after 10 years of stability.

Arquivos de neuro-psiquiatria

Double-seronegative neuromyelitis optica: it is possible to interrupt treatment after 10 years of stability.

Journal francais d'ophtalmologie

[Neuromyelitis optica spectrum disorder with positive aquaporin-4 antibodies and anti-myelin oligodendrocyte glycoprotein antibodies].

Comparative Effectiveness of Disease-Modifying Treatments in Double Seronegative Neuromyelitis Optica Spectrum Disorder.

European journal of neurology

Age, Low Immunoglobulin G, and M Serum Levels Predict Infections in People With AQP4-IgG+ NMOSD Treated With Rituximab-A Multicenter Cohort Study From the German Neuromyelitis Optica Study Group (NEMOS).

Activation status of astrocytes drives the MS/NMOSD therapeutic paradox: Insights from IFNAR1 signaling.

Cell reports

European journal of immunology

Microbial-Immune Interplay in CNS Autoimmune Diseases: Lessons from Animal Models and Clinical Studies.

Natural killer cell reduction and dysfunction define a pathogenic and diagnostic axis in neuromyelitis optica spectrum disorder.

Journal of neuroimmunology

Bilateral optic neuritis preceding a Baló concentric sclerosis lesion: A case report and literature review.

Evaluation of blood-brain barrier integrity and clinical characteristics in autoimmune glial fibrillary acidic protein astrocytopathy.

Multiple sclerosis (Houndmills, Basingstoke, England)

Predictive factors for immunosuppression-associated severe and opportunistic infections in AQP4-IgG Neuromyelitis Optica Spectrum Disorder.

Diagnostic biomarkers for differentiating AQP4-IgG- negative NMOSD from other nervous system autoimmune disorders: a retrospective study.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques

Demographic and clinical characteristics of aquaporin-4 antibody positive neuromyelitis optica spectrum disorder in Canadian adults.

Isolated Paramedian Pontine Reticular Formation (PPRF) syndrome in AQP4 antibody-positive neuromyelitis optica spectrum disorder: a case report.

Case Report: Organizing pneumonia associated with AQP4-antibody neuromyelitis optica spectrum disorder in children.

Frontiers in pediatrics

Case reports in neurological medicine

Double Anti-NMO and Anti-MOG Positivity in a Patient With Metastatic Renal Carcinoma: First Reported Case.

Multiple sclerosis journal - experimental, translational and clinical

The impact of relapse on patient disability, clinical outcomes, and subsequent burdens to patients with neuromyelitis optica spectrum disorder and caregivers.

Outcomes and predictors of relapse and severe pneumonia in Chinese patients with AQP4-IgG-positive neuromyelitis optica spectrum disorder receiving inebilizumab: a prospective cohort study.

Journal of clinical medicine

Hearing Loss in Neuromyelitis Optica Spectrum Disorder: Case Report and Systematic Review.

International journal of molecular sciences

Changes in Blood Cells and Complements During Relapse Prevention Therapies for Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder.

Unexpected pregnancy in a patient with AQP4-IgG + NMOSD after treatment with inebilizumab: a case report.

Therapeutic effects of IGF-2 on NMOSD by inhibiting astrocyte apoptosis through modulation of the IGF-1R/PI3K/AKT signaling pathway.

Scientific reports

European journal of internal medicine

Tongue atrophy following unexplained nausea, vomiting, and hiccups.

Consensus Recommendations for the Diagnosis and Treatment of Neuromyelitis Optica Spectrum Disorders (NMOSD): The MENACTRIMS Guidelines.

CNS drugs

Brain, behavior, & immunity - health

AQP4-IgG and mood disorders: Case series of neuromyelitis optica spectrum disorder.

Low prevalence of inflammatory bowel disease among patients with seropositive neuromyelitis optica spectrum disorder in two large referral centers.

Baseline severe disability as a predictor of treatment escalation to rituximab in AQP4-IgG-positive NMOSD patients: A retrospective cohort study.

Neurological and paraclinical features differentiating Systemic lupus erythematosus, Sjögren's disease, and neuromyelitis optica spectrum disorders.

Dysregulated Tfh/B cells and their interactions in neuromyelitis optica spectrum disorder.

Ravulizumab in NMOSD with associated interstitial pneumonitis in a 59-year-old female patient: a case report.

Efficacy of fresh frozen plasma and human albumin in therapeutic plasma exchange for refractory neuromyelitis optica spectrum disorders and multiple sclerosis exacerbation: A two-tertiary care center study.

Case reports in neurology

Neuromyelitis Optica Spectrum Disorder Developing after COVID-19 Vaccination Managed with Long-Term Eculizumab Treatment: A Case Report.

Dermatomal pruritus as a heralding symptom in AQP4-positive LETM with anti-Ro52 positivity.

BMJ case reports

Case reports in ophthalmology

Urinary Tract Infection Masquerading as a Neuromyelitis Optica Spectrum Disorder Exacerbation: A Case Report.

Translational vision science & technology

Prognostic Modeling for the Failure of Intravenous Methylprednisolone and the Risk of Visual Disability in AQP4-IgG Positive NMOSD-ON.

Pain in NMOSD is not always neuropathic: multifocal avascular osteonecrosis mimicking neuropathic pain.

BMJ case reports

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

Relapse-related outcomes in the Danish population-based AQP4- antibody seropositive neuromyelitis optica spectrum disorder cohort.

Handbook of clinical neurology

The future unfolded: CAR T cells and the transformation of treatment algorithms in autoimmune neurology.

Handbook of clinical neurology

Immunotherapies for neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease.

Handbook of clinical neurology

The evolution and current status of anti-B-cell therapies in autoimmune neurologic diseases.

Investigating the Frequency and Outcome of Central Vein Sign and Paramagnetic Rim Lesions in Children With MOGAD.

Journal of child neurology

Outcomes of Children With Optic Neuritis as Their First Demyelinating Event.

Eculizumab as a rescue therapy in acute-phase aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder.

Myelitis-Predominant Aggressive Phenotype: Unveiling Unique Patterns of Late-Onset Neuromyelitis Optica Spectrum Disorders.

Annals of neurology

Annals of Indian Academy of Neurology

Persistent Pathological Yawning due to Neuromyelitis Optica Spectrum Disorder.

Real-world effectiveness and safety of eculizumab in AQP4-IgG-positive neuromyelitis optica spectrum disorder.

OCT-Based Differentiation of First Acute Optic Neuritis: An International Study of 111 Patients With NMOSD and MOGAD.

Patient Preferences for Neuromyelitis Optica Spectrum Disorder (NMOSD) Treatments: Results from a Discrete Choice Experiment Study in the USA.

The patient

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

Aquaporin-4-IgG positive radiologically isolated neuromyelitis optica spectrum disorder: treat or observe?

bioRxiv : the preprint server for biology

Astrocyte-derived extracellular vesicles as antigen-specific therapy for neuromyelitis optica spectrum disorder in the mouse model.

Folate metabolism disorder presenting as an opticospinal syndrome.

Practical neurology

Real-World Efficacy and Safety of Neuromyelitis Optica Spectrum Disorder Disease-Modifying Treatments.

Cerebrospinal Fluid Autoantibody Profiles in Rheumatologic Disorders Affecting the Central Nervous System: A Systematic Review.

Lipids in health and disease

Remnant cholesterol and lipid ratios predict the relapse of neuromyelitis optica spectrum disorder.

Screening for Biotinidase deficiency in children with spinal cord demyelination.

Apathy in patients with Neuromyelitis Optica Spectrum Disorder.

PloS one

CAR T cells as novel therapeutic strategy for multiple sclerosis and other neuroimmune disorders.

Journal of clinical medicine

Prescription Drug Use in NMOSD: A Population-Based Study in Greece with Estimation of National Disease Administrative Prevalence.

Glymphatic dysfunction in neuromyelitis optica spectrum disorder.

Multiple sclerosis (Houndmills, Basingstoke, England)

Optimizing kappa free light chain index thresholds for multiple sclerosis (MS) diagnosis in low-MS prevalence regions: Insights from an Asian cohort.

Progress in retinal and eye research

Glymphatic transport and ocular diseases.

Cerebellar microstructural and functional connectivity changes in patients with neuromyelitis optica spectrum disorders and their correlation with cognitive function: a female-dominated multimodal MRI study.

The Optic Nerve as a New Diagnostic Frontier in Multiple Sclerosis: How the 2024 McDonald Criteria Leverage Multimodal Evaluation for Earlier Diagnosis.

Mitochondrial-Immune Overlap in Leber Hereditary Optic Neuropathy: A Case Report and Lessons Learned.

Reports (MDPI)

Serum Aquaporin-4 Antibody Status and TGF-β in Neuromyelitis Optica Spectrum Disorder: Impact on Astrocyte Function and Correlation with Disease Activity and Severity.

Neurology international

Complement C4d Informs the Differential Diagnosis of Inflammatory Demyelinating CNS Diseases.

Progression Independent of Relapse Activity in Aquaporin-4-IgG-Positive NMOSD: A Decade-Long Cohort Study.

Neuromyelitis Optica Spectrum Disorder Presenting With Longitudinally Extensive Transverse Myelitis and Pontine Involvement in a Patient With Systemic Lupus Erythematosus.

The impact of physical and psychological health outcomes on stigma in people with neuromyelitis optica spectrum disorder: A cross-sectional study.

Medicine

International ophthalmology clinics

Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): Mechanisms, Syndromes, and Management.

International ophthalmology clinics

Neuromyelitis Optica Spectrum Disorder.

Autoimmune thyroid disease and human health: a systematic review of Mendelian randomization studies.

Cognitive performances in people with neuromyelitis optica spectrum disorder: a systematic review and meta-analysis.

Progressive Cerebral Atrophy and Cognitive Decline Without Cerebral Lesion in Neuromyelitis Optica Spectrum Disorder: A Case Report.

The American journal of case reports

Drug-Induced Lupus Erythematosus After 14 Years of Carbamazepine Use in a Patient With Neuromyelitis Optica Spectrum Disorder: A Case Report.

Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society

Very-Late-Onset Neuromyelitis Optica Spectrum Disorder Presenting as Isolated Optic Neuritis in an 85-Year-Old Woman: A Diagnostic and Management Challenge.

Complement activation in immunological neurological disorders: mechanisms and therapeutic strategies.

Brain atrophy in NMOSD and MOGAD: a meta-analysis of volumetric and DTI biomarkers.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques

Impact of Autoantibody Status on Visual Outcomes in Severe Optic Neuritis Patients Without Multiple Sclerosis.

Modern rheumatology case reports

Anti-SRP antibody-positive polymyositis complicated by neuromyelitis optica spectrum disorder: a case report and literature review.

Multifocal Presentations of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): A Case Series From a District General Hospital in South East England.

Efficacy of a fixed-interval, body surface area-adjusted rituximab regimen in Singaporean patients with CNS inflammatory demyelinating diseases.

Multiple sclerosis research in 2025: earlier diagnosis and halting progression.

The Lancet. Neurology

Annals of Indian Academy of Neurology

Tocilizumab in Refractory Neuro Myelitis Optica Spectrum Disorder and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease - Experience from a Tertiary Care Centre.

Short and Long-Term Effects of Intravenous Methylprednisolone and Plasma Exchange Combination in NMOSD Attacks.

Noro psikiyatri arsivi

Multiple sclerosis journal - experimental, translational and clinical

Satralizumab treatment in adults with aquaporin-4 immunoglobulin G-seropositive neuromyelitis optica spectrum disorder in clinical practice.

Cellular therapy in neuromyelitis optica spectrum disorder.

Therapeutic advances in neurological disorders

Brain volumetry and spinal cord imaging in patients with AQP4-IgG+ NMOSD-a systematic review and meta-analysis.

Inflammatory transcriptomic signatures in a human cellular NMOSD model reveal upregulation of NF-κB and IL6 pathways.

Scientific reports

Cognitive impairment and multiparametric brain MRI in aquaporin-4-IgG positive neuromyelitis optica spectrum disorder.

Decoding tRNA dynamics in neuroimmune disorders: mechanistic insights, diagnostic innovations, and therapeutic opportunities.

Alterations in the Expression of Let-7i, miR-21-5p, and miR-30b-5p in Plasma-Derived Extracellular Vesicles as the Possible Prognostic Markers in Central Demyelinating Diseases.

Molecular neurobiology

Evaluation of the Efficacy and Safety of Satralizumab in a Pregnant NMOSD Patient With AQP4/MOG-IgG Dual Seropositive: A Case Report.

Journal of neuroimmunology

Characterizing double seronegative neuromyelitis optica spectrum disorder: A distinct subgroup or part of the continuum?

Adherence to the MIND diet and onset of neuromyelitis optica spectrum disorder: A case-control study.

International medical case reports journal

Neuromyelitis Optica-Associated Acute Intermediate Uveitis.

Herpes simplex virus associated rhomboencephalitis mimicking demyelination: a case report.

BMC infectious diseases

Inebilizumab: Pediatric Case Series in Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder.

Pediatric neurology

A real-world comparative study on the efficacy and safety of tocilizumab and rituximab in patients with neuromyelitis optica spectrum disease and myelin oligodendrocyte glycoprotein antibody-associated disease.

Experience of bortezomib use in refractory autoimmune neurological disorders.

Effect of hyperbaric oxygen therapy on peripheral blood inflammatory markers in patients with neuromyelitis optica spectrum disorder: a retrospective cohort study.

Microglial estrogen receptor 1 signal designates sexual dimorphism of AQP4 antibody-induced neuroinflammation and demyelination.

Cell reports

Pain in neuromyelitis optica spectrum disorder: determination of prevalence and characteristics.

Acta neurologica Belgica

Atypical Neuromyelitis Optica Spectrum Disorder: A Case of Unilateral Optic Neuritis and Partial Transverse Myelitis.

Bruton Tyrosine Kinase Inhibition Limits Multiple Sclerosis Disease-Driving Inflammation While Promoting Regulatory B Cells.

Nationwide Survey of Atopic Myelitis and Plexin D1-Immunoglobulin G-Related Pain.

Peripheral blood immune inflammatory markers in neuromyelitis optica spectrum disorders.

Effects of eculizumab and rituximab on visual function, motor function and social quality in patients with NMOSD: a comparative study.

Choroidal structure differs between multiple sclerosis and neuromyelitis optica spectrum disorder: An enhanced depth imaging optical coherence tomography study.

Inebilizuma treatment for acute serum AQP4 - IgG neuromyelitis optica: Case report.

Medicine

Transcriptional expression patterns of orientation dispersion index of white matter in neuromyelitis optica spectrum disorder.

Clinical radiology

Clinical reviews in allergy & immunology

CAR T Cell Therapy for Rheumatoid Arthritis.

Severe attacks and worse prognosis in patients with late-onset neuromyelitis optica spectrum disorder highlight the need for early highly effective treatment.

World journal of clinical cases

Beyond the optic disc: Investigating gender-based differences in optic neuritis.

Expanding Evidence of Leptomeningeal Involvement in MOGAD and Its Relevance to Its Pathophysiology.

B cell receptor repertoire reconstitution in patients with neuromyelitis optica spectrum disorder receiving B-cell depletion therapy.

Rinsho shinkeigaku = Clinical neurology

Clinical features of three cases of neurosarcoidosis with a positive aquaporin-4 antibody requiring differentiation from neuromyelitis optica spectrum disorder.

Social alienation and related factors in patients with neuromyelitis optica spectrum disorder: a cross-sectional study.

Risk of hepatitis B and tuberculosis reactivation in patients with neuromyelitis optica spectrum disorder undergoing B cell depletion therapy.

Real-World Investigation of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disease.

Consensus recommendations for the diagnosis and management of neuromyelitis optica spectrum disorder: A Saudi expert panel review.

Dual ROCK1/2-MYLK4 Kinase Inhibition Preserves Visual Function in a Rat Model of Neuromyelitis Optica Spectrum Disorder Optic Neuritis.

Cells

Diagnostics (Basel, Switzerland)

Hyperperfusion Improvement: A Potential Therapeutic Marker in Neuromyelitis Optica Spectrum Disorder (NMOSD).

Double-negative NMOSD: from case report to a proposed diagnostic and therapeutic algorithm.

Journal of neuroimmunology

The real-world experience of biologics for neuromyelitis optica spectrum disorders as first-line and switched therapy.

Arquivos de neuro-psiquiatria

2025 Brazilian guidelines for the management of neuromyelitis optica spectrum disorder in adults and children.

Anterograde and trans-synaptic neurodegeneration in aquaporin-4-antibody neuromyelitis optica spectrum disorder patients with a history of transverse myelitis.

Brain communications

Immunity, inflammation and disease

Chimeric Antigen Receptor T-Cell Therapy and Autoimmune Diseases in the Nervous System.

Clinical value of plasma C1q, C3, and C4 in NMOSD and MOGAD.

Ver todos os 1.718 no EuropePMC

Próxima:Associações

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Espectro clínico de neuromielite óptica.

É de uma associação que acompanha esta doença? Fale com a gente →

Próxima:Comunidades

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Espectro clínico de neuromielite óptica

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Próxima:Tire suas dúvidas

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Próxima:Doenças relacionadas

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Ordenadas pelo número de sintomas em comum.

Neuropatia óptica autoimune/inflamatória

17 em comum

ORPHA:499047

Encefalite infecciosa

6 em comum

ORPHA:98252

Encefalite disseminada aguda

6 em comum

ORPHA:83597

Uveíte

5 em comum

ORPHA:98715

Tripanossomíase Africana

Encefalite por picada de carrapato

ORPHA:3385

Mielite transversa, aguda

ORPHA:297

ORPHA:139417

Listeriose

Lúpus eritematoso sistêmico

ORPHA:533

Doença das células dos cornos anteriores, adquirida

ORPHA:536

ORPHA:98506

Doença de Krabbe